Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...
The agency outlined the adjustments it's willing to make to "remove barriers and perceived misconceptions" for innovative medicines.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 /PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale Creating readiness for first production runs of potential commercial launches, including ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback